Astrazeneca’s (AZN) Sell Rating Reaffirmed at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft restated their sell rating on shares of Astrazeneca (NYSE:AZN) in a report issued on Thursday,MarketScreener reports.

Other research analysts also recently issued research reports about the stock. Barclays reissued an “overweight” rating on shares of Astrazeneca in a research report on Tuesday, January 6th. DZ Bank raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Thursday. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Thursday, April 23rd. Finally, UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. Eleven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $102.67.

Astrazeneca Trading Down 0.3%

NYSE AZN traded down $0.52 during trading on Thursday, reaching $186.85. 218,721 shares of the company’s stock traded hands, compared to its average volume of 2,757,192. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.72 and a current ratio of 0.94. The company has a market capitalization of $289.79 billion, a price-to-earnings ratio of 31.62, a price-to-earnings-growth ratio of 1.40 and a beta of 0.35. Astrazeneca has a 12-month low of $132.32 and a 12-month high of $212.71.

Astrazeneca (NYSE:AZN) last posted its earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.51 by $0.07. The business had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.98 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 31.01%. Equities analysts forecast that Astrazeneca will post 10.26 EPS for the current fiscal year.

Astrazeneca Announces Dividend

The firm also recently disclosed a dividend, which was paid on Monday, March 23rd. Shareholders of record on Friday, February 20th were paid a dividend of $1.595 per share. This represents a yield of 156.0%. The ex-dividend date was Friday, February 20th. Astrazeneca’s payout ratio is presently 73.43%.

Institutional Trading of Astrazeneca

Institutional investors and hedge funds have recently bought and sold shares of the business. IHT Wealth Management LLC raised its stake in shares of Astrazeneca by 0.3% in the 4th quarter. IHT Wealth Management LLC now owns 17,527 shares of the company’s stock valued at $3,076,000 after acquiring an additional 54 shares in the last quarter. Visionary Wealth Advisors raised its stake in shares of Astrazeneca by 1.5% in the 4th quarter. Visionary Wealth Advisors now owns 4,197 shares of the company’s stock valued at $737,000 after acquiring an additional 60 shares in the last quarter. Vista Investment Management grew its holdings in Astrazeneca by 0.3% in the 4th quarter. Vista Investment Management now owns 21,215 shares of the company’s stock valued at $3,723,000 after buying an additional 60 shares during the last quarter. Kestra Investment Management LLC grew its holdings in Astrazeneca by 1.9% in the 4th quarter. Kestra Investment Management LLC now owns 3,391 shares of the company’s stock valued at $595,000 after buying an additional 63 shares during the last quarter. Finally, Luken Investment Analytics LLC grew its holdings in Astrazeneca by 4.3% in the 4th quarter. Luken Investment Analytics LLC now owns 1,564 shares of the company’s stock valued at $274,000 after buying an additional 64 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Astrazeneca

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: FDA panel backed AstraZeneca’s prostate cancer regimen, giving regulatory momentum to part of its oncology franchise — a near?term positive for future approvals and revenues. Read More.
• Positive Sentiment: Strong Q1 results: AZN beat EPS and revenue expectations and reaffirmed 2026 guidance, supporting the company’s growth narrative driven by oncology and rare?disease sales. Read More.
• Positive Sentiment: Citi raised its 2026 core EPS forecast and kept a Buy rating, highlighting attractive risk/reward ahead of multiple second?half pipeline readouts. Analyst support can help underpin the stock. Read More.
• Positive Sentiment: DZ Bank upgraded AZN from Neutral to Buy, adding institutional endorsement to the bullish view after the earnings beat. Read More.
• Positive Sentiment: AstraZeneca exercised its option to license Pinetree’s EGFR degrader program (PTX?299), triggering a $25M payment and expanding its targeted?degrader pipeline — a financing and pipeline positive. Read More.
• Neutral Sentiment: Erste Group slightly trimmed its FY2026 EPS estimate for AZN (from $10.44 to $10.30), a modest forecast tweak that reflects caution but is close to consensus. Read More.
• Negative Sentiment: The key negative: an FDA Oncologic Drugs Advisory Committee voted 6–3 against recommending camizestrant for first?line treatment in HR+ advanced breast cancer, citing trial?design and benefit?risk concerns — the vote has driven today’s share weakness and raises regulatory risk and potential delays for that indication. AstraZeneca says it will continue working with regulators. Read More.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.